方法对比
并排查看您选择的方法;存在差异的行会高亮显示。
| 风险调整的IV期研究× | 逆概率治疗加权法 (IPW / IPTW)× | |
|---|---|---|
| 领域≠ | 流行病学 | 因果推断 |
| 方法族≠ | Process / pipeline | Regression model |
| 起源年份≠ | 1990s–2000s (formalized with ICH E2E and EMA PASS guidelines) | 2000 |
| 提出者≠ | Regulatory and pharmacoepidemiology community (ICH, EMA, FDA frameworks) | Robins, Hernán & Brumback |
| 类型≠ | Observational / quasi-experimental clinical study design | Causal inference weighting estimator |
| 开创性文献≠ | Strom, B. L. (Ed.). (2005). Pharmacoepidemiology (4th ed.). John Wiley & Sons. ISBN: 978-0470863107 | Robins, J. M., Hernán, M. A., & Brumback, B. (2000). Marginal Structural Models and Causal Inference in Epidemiology. Epidemiology, 11(5), 550-560. DOI ↗ |
| 别名≠ | risk-adjusted post-marketing surveillance study, adjusted Phase IV trial, risk-stratified post-authorization study, PASS with risk adjustment | IPW, IPTW, inverse probability of treatment weighting, marginal structural model weighting |
| 相关≠ | 3 | 5 |
| 摘要≠ | A risk-adjusted Phase IV study is an observational or semi-experimental post-marketing study conducted after a drug or device has received regulatory approval. It uses statistical risk-adjustment techniques — such as propensity score matching, inverse probability weighting, or multivariable regression — to control for confounding by indication and baseline patient differences, thereby producing more credible safety, effectiveness, and utilization estimates than unadjusted real-world analyses. | Inverse Probability Weighting is a causal-inference method that assigns each observation a weight equal to the inverse of its probability of receiving the treatment it actually received. Introduced by Robins, Hernán and Brumback (2000) for marginal structural models, it builds a pseudo-population in which treatment is independent of measured confounders, balancing selection bias. |
| ScholarGate数据集 ↗ |
|
|